XFOR
NASDAQ · Biotechnology
X4 Pharmaceuticals Inc
$4.22
+0.17 (+4.20%)
Open$4.03
Previous Close$4.05
Day High$4.28
Day Low$4.02
52W High$4.83
52W Low$1.35
Volume—
Avg Volume495.0K
Market Cap398.03M
P/E Ratio—
EPS$-4.64
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+573.5% upside
Current
$4.22
$4.22
Target
$28.42
$28.42
$21.41
$28.42 avg
$38.37
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 81.59M | 38.69M | 57.05M |
| Net Income | -184,036,862 | -510,081,137 | 9.29M |
| Profit Margin | -225.6% | -1,391.4% | 16.3% |
| EBITDA | -198,926,099 | -479,400,827 | 17.50M |
| Free Cash Flow | — | — | 7.43M |
| Rev Growth | — | -5.2% | +3.4% |
| Debt/Equity | 0.41 | 3.41 | 0.94 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.89 | +0.06% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $351.43 | +1.27% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.16 | +0.09% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $475.20 | +1.45% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $623.43 | +0.87% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $294.06 | +2.04% | 64.3 | 37.13B |